Pharmacogenetic Response to Naltrexone For Alcohol Dependence
Status:
Completed
Trial end date:
2014-01-15
Target enrollment:
Participant gender:
Summary
The aims of the study are to test for treatment outcome differences in alcohol dependent
subjects randomly assigned to 12 weeks of treatment with NTX (50mg/day) or placebo among
those with one or two copies of the Asp40 allele of the mu-opioid receptor compared to those
homozygous for the Asn40 allele. Thus, the design of the study is a 2X2 cell double-blind
randomization to NTX or placebo stratified by genotype. To meet these aims, 150 alcohol
dependent outpatients with one or two copies of the Asp40 variant of the mu-opioid receptor
and 190 subjects homozygous for the Asn40 variant will be recruited across the four
participating sites.
Phase:
Phase 4
Details
Lead Sponsor:
David Oslin
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)